{"id":5314,"date":"2024-04-03T00:07:14","date_gmt":"2024-04-02T16:07:14","guid":{"rendered":"https:\/\/flcube.com\/?p=5314"},"modified":"2024-10-13T18:49:51","modified_gmt":"2024-10-13T10:49:51","slug":"junshi-biosciences-files-for-approval-of-ongericimab-targeting-key-cholesterol-disorders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=5314","title":{"rendered":"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders"},"content":{"rendered":"\n

China’s Junshi Biosciences (HKG: 1877<\/a>; SHA: 688180<\/a>) has announced the submission of two market approval filings for its PCSK9 monoclonal antibody, ongericimab (JS002). The filings target heterozygous familial hypercholesterolemia and primary hypercholesterolemia, as well as mixed dyslipidemia in patients who are intolerant to or contraindicated for statins. The National Medical Products Administration (NMPA) has accepted these submissions for review.<\/p>\n\n\n\n

The filings are supported by robust data from two randomized, double-blinded, placebo-controlled Phase III studies: JS002-005 and JS002-007, both demonstrating significant efficacy and tolerability for ongericimab.<\/p>\n\n\n\n

Ongericimab has successfully completed two Phase III clinical trials focusing on primary hypercholesterolemia (including both heterozygous familial and non-familial cases) and mixed hyperlipidemia. Additionally, the drug has undergone a Phase II study for homozygous familial hypercholesterolemia and a Phase III trial specifically targeting heterozygous hypercholesterolemia. A major analysis has also been completed for a Phase III study involving patients with primary hypercholesterolemia and mixed hyperlipidemia who are statin intolerant and have moderate to low cardiovascular risk.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has announced the submission of two market approval…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[899,38,900],"class_list":["post-5314","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-1877","tag-market-approval-filings","tag-sha-688180"],"yoast_head":"\nJunshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Junshi Biosciences (HKG: 1877; SHA: 688180) has announced the submission of two market approval filings for its PCSK9 monoclonal antibody, ongericimab (JS002). The filings target heterozygous familial hypercholesterolemia and primary hypercholesterolemia, as well as mixed dyslipidemia in patients who are intolerant to or contraindicated for statins. The National Medical Products Administration (NMPA) has accepted these submissions for review.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=5314\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=5314\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-02T16:07:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T10:49:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5314#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5314\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders\",\"datePublished\":\"2024-04-02T16:07:14+00:00\",\"dateModified\":\"2024-10-13T10:49:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5314\"},\"wordCount\":176,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1877\",\"Market approval filings\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5314#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5314\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=5314\",\"name\":\"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-02T16:07:14+00:00\",\"dateModified\":\"2024-10-13T10:49:51+00:00\",\"description\":\"China's Junshi Biosciences (HKG: 1877; SHA: 688180) has announced the submission of two market approval filings for its PCSK9 monoclonal antibody, ongericimab (JS002). The filings target heterozygous familial hypercholesterolemia and primary hypercholesterolemia, as well as mixed dyslipidemia in patients who are intolerant to or contraindicated for statins. The National Medical Products Administration (NMPA) has accepted these submissions for review.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5314#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5314\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5314#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders - Insight, China's Pharmaceutical Industry","description":"China's Junshi Biosciences (HKG: 1877; SHA: 688180) has announced the submission of two market approval filings for its PCSK9 monoclonal antibody, ongericimab (JS002). The filings target heterozygous familial hypercholesterolemia and primary hypercholesterolemia, as well as mixed dyslipidemia in patients who are intolerant to or contraindicated for statins. The National Medical Products Administration (NMPA) has accepted these submissions for review.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=5314","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=5314","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-02T16:07:14+00:00","article_modified_time":"2024-10-13T10:49:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=5314#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=5314"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders","datePublished":"2024-04-02T16:07:14+00:00","dateModified":"2024-10-13T10:49:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=5314"},"wordCount":176,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1877","Market approval filings","SHA: 688180"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=5314#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=5314","url":"https:\/\/flcube.com\/?p=5314","name":"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-02T16:07:14+00:00","dateModified":"2024-10-13T10:49:51+00:00","description":"China's Junshi Biosciences (HKG: 1877; SHA: 688180) has announced the submission of two market approval filings for its PCSK9 monoclonal antibody, ongericimab (JS002). The filings target heterozygous familial hypercholesterolemia and primary hypercholesterolemia, as well as mixed dyslipidemia in patients who are intolerant to or contraindicated for statins. The National Medical Products Administration (NMPA) has accepted these submissions for review.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=5314#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=5314"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=5314#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Files for Approval of Ongericimab, Targeting Key Cholesterol Disorders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5314"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5314\/revisions"}],"predecessor-version":[{"id":6008,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5314\/revisions\/6008"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}